TRIAL DETAIL
The Biological Activity of AZD2171 in GIST
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
The Biological Activity of AZD2171 in GIST |
|||
NCT#: |
||||
Conditions: |
Gastrointestinal Stromal Tumors; Soft Tissue Sarcomas |
|||
Status: |
Completed |
|||
Phase: |
2 |
Start Date 09/01/2006 |
Age of Trial (yrs) 18.3 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
KIT/PDGFRA inhibitor
VEGFR inhibitor (TKI) |
|||
Strategy: |
Block KIT
Block tumor blood vessel growth |
|||
Trial Type: |
Specifically GIST plus other cancers |
|||
Other Protocol IDs: |
D8480C00046 |
|||
Sponsor: |
AstraZeneca |
|||
Patient Contact: |
AstraZeneca Cancer Support Network |
|||
Contact email: |
information.center@astrazeneca.com |
|||
Contact Phone: |
1-866-992-9276 |
|||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
Note: AstraZeneca maintains a central point of contact for this trial. Contact: AstraZeneca Cancer Support Network, 1-866-992-9276(USA), information.center@astrazeneca.com Contact: Outside US, 001-866-992-9276. |
|||
Trial Links |
Trial Results |
Drug Information |
| Ongoing studies |
| The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
550 Wilmslow Rd |
Manchester |
Lancashire |
M20 4BX |
UK |
|
Downs Rd |
Sutton |
Surrey |
SM2 5PT |
UK |